APA (7th ed.) Citation

Wu, W., Deng, H., Rao, N., You, N., Yang, Y., Cao, M., . . . Liu, J. (2017). Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: Study protocol for a randomized pilot trial. Trials, 18, 1. https://doi.org/10.1186/s13063-017-2228-5

Chicago Style (17th ed.) Citation

Wu, Wei, et al. "Neoadjuvant Everolimus Plus Letrozole Versus Fluorouracil, Epirubicin and Cyclophosphamide for ER-positive, HER2-negative Breast Cancer: Study Protocol for a Randomized Pilot Trial." Trials 18 (2017): 1. https://doi.org/10.1186/s13063-017-2228-5.

MLA (9th ed.) Citation

Wu, Wei, et al. "Neoadjuvant Everolimus Plus Letrozole Versus Fluorouracil, Epirubicin and Cyclophosphamide for ER-positive, HER2-negative Breast Cancer: Study Protocol for a Randomized Pilot Trial." Trials, vol. 18, 2017, p. 1, https://doi.org/10.1186/s13063-017-2228-5.